NutrigeneAI

NutrigeneAI Biotech Limited (NutrigeneAI) is an innovative biotechnology enterprise focusing on regenerative medicine. The company was spun off from the Chinese University of Hong Kong (CUHK) in 2023 and is committed to promoting the industrialization of scientific research achievements. Led by Professor Yeung Tak Wong of CUHK's School of Life Sciences, the core team includes biotechnology experts and professionals with extensive pharmaceutical experience. NutrigeneAI focuses on developing innovative vascular regeneration therapies based on induced pluripotent stem cell (iPSC)-derived endothelial cells. By leveraging AI and biotechnology, the company aims to repair damaged blood vessels, particularly complications caused by metabolic diseases such as diabetes. NutrigeneAI has developed the world’s first Type II cytokine-based vascular repair biologic drug, which promotes vascular regeneration and microcirculation reconstruction, offering non-invasive treatment options for patients with critical limb ischemia (CLI), diabetic foot, and peripheral artery disease (PAD).